0GT Stock Chart & Stats
€29.46
-€1.65(-15.71%)
At close: 4:00 PM EST
€29.46
-€1.65(-15.71%)
Day’s Range― - ―
52-Week Range€9.95 - €32.80
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
€1.71B
Enterprise Value€1.73B
Total Cash (Recent Filing)€343.55M
Total Debt (Recent Filing)€3.42M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 10, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume8
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€41.88Price Target Upside42.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.83
Revenue Forecast (FY)€22.94M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero debt provides durable financial flexibility to fund late-stage development, support a rolling NDA, and pursue partnerships or M&A without heavy interest burdens. Low leverage reduces bankruptcy risk and extends runway relative to peers while commercialization is still years away.
Phase 3 Completion & Regulatory PathCompleting Phase 3 enrollment and beginning a rolling NDA materially de-risks the development timeline. This structural progress advances Stoke from exploratory to regulatory review, increases the probability of approval-driven revenue and milestone payments, and shortens the timeline to potential commercialization.
High Gross Profitability When Revenue PresentA high gross margin implies favorable unit economics for ASO therapies: if products are approved, scaled sales could generate substantial gross profit. That profitability can absorb fixed R&D and SG&A over time, supporting sustainable operating leverage post-commercialization.
Bears Say
Elevated Cash BurnSubstantial negative operating and free cash flow indicate persistent burn that will require external funding if it continues. This creates durable financing risk: potential dilution, restrictive financing terms, or curtailed development timelines if regulatory or clinical setbacks delay revenue generation.
Sharp Revenue Decline And Loss-Making OperationsAn ~82.6% TTM revenue decline and deeply negative margins highlight reliance on non-recurring or milestone receipts rather than stable product revenue. Persistent operating losses undermine internal self-funding capacity and heighten dependence on financing until commercial sales commence.
Reliance On Partnership/Milestone MonetizationThe company's near-term revenue model depends on contingent partner deals and milestone payments, creating structural revenue timing uncertainty. Dependence on partners can limit captured upside, dilute strategic control over commercialization, and amplify funding risk if milestones are delayed.
Stoke Therapeutics News
0GT FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was €9.95 and its highest was €32.80 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is €1.71B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 29 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on May 07, 2026. The company reported -€0.692 earnings per share for the quarter, beating the consensus estimate of -€0.708 by €0.016.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 62,281,654 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -€0.692 in its last earnings report, beating expectations of -€0.708. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in DE:0GT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€41.88 (42.16% Upside)
€41.88 (42.16% Upside)
Blogger Sentiment
Bullish
DE:0GT Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
160.63%
12-Months-Change
Fundamentals
Return on Equity
-48.84%
Trailing 12-Months
Asset Growth
8.94%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
0GT Company Deck
0GT Earnings Call
Q1 2026
0:00 / 0:00
0GT Stock 12 Month Forecast
Average Price Target
€41.88
▲(42.16% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Options Prices
Currently, No data available
---